Positive high-level results from AstraZeneca's MANDARA Phase III study revealed that FASENRA(benralizumab)

MBX Biosciences, Inc. released favorable outcomes from the Phase 1 trial's multiple ascending dose section for MBX 2109.

EyePoint Pharmaceuticals, Inc., a company focused on improving life quality for severe eye condition patients, has revealed promising safety data for its key product candidate EYP-1901.

Updated results from a subgroup analysis of a phase 1/2 trial showed that ifinatamab deruxtecan (I-DXd) continues to demonstrate durable responses in patients with heavily pretreated advanced small cell lung cancer.

Bristol Myers Squibb's experimental LPA1 Antagonist showed promising results in reducing the rate of lung function decline in the Progressive Pulmonary Fibrosis group in a phase 2 clinical trial.

Promising clinical responses were observed in TROPION-Lung04's Phase 1b Trial with a combination of Datopotamab Deruxtecan and Durvalumab with Non-Small Cell Lung Cancer.

The HERTHENA-Lung01 Phase 2 Trial showed that Patritumab Deruxtecan brought about meaningful and durable effects in Patients with non-small cell lung cancer.

Samsung Bioepis Co., Ltd. disclosed it has struck a commercialization pact with Sandoz regarding SB17, a potential biosimilar to Stelarai(ustekinumab).

OKYO Pharma Limited has successfully enrolled its patient quota for the Phase 2 clinical trial.

Carrick Therapeutics made an announcement that their IND application for CT7439 has been given the green light by U.S FDA.

Opus Genetics has administrated to the first patient in its first-in-human Phase 1/2 clinical trial for OPGx-LCA5.

Eloxx Pharmaceuticals, Inc. provided new information on the development of ELX-02 in the context of handling Alport syndrome caused by nonsense mutations.